Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nanotech Safety, Efficacy Models Exist, But Nomenclature Problematic – FDA

This article was originally published in The Gray Sheet

Executive Summary

FDA expects nanotechnology will be subject to the same efficacy standards demanded of medical devices, according to CDRH Office of Science & Engineering Laboratories Director Larry Kessler

You may also be interested in...

Multi-Agency Nanotech Toxicity Initiative Funded At $105.9 Mil. In FY 2004

FDA will continue to monitor potential safety threats associated with some nanotechnology drug delivery devices, according to FDA Associate Commissioner for Science Norris Alderson, PhD

Nano-Oncology Strategic Plan Incorporates NCI-Housed Standardization Lab

A series of nanotechnology public meetings - including forums dedicated to imaging and detection applications - will be held in early- to mid-2004 by NCI's newly formed Cancer Nanotechnology Extramural Working Group

Esperion Aiming For 50% Commercial Coverage For Nexletol

The company hopes to sidestep payer restrictions and patient abandonment by launching the cholesterol-lowering medicine at a palatable price point in line with where branded statins were before patent expiry.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts